IN VITRO EFFECTS OF CHELIDONIUM MAJUS L ALKALOID THIOPHOSPHORIC ACID CONJUGATES (UKRAIN) ON THE PHENOTYPE OF NORMAL HUMAN LYMPHOCYTES

ŚLESAK B.¹, NOWICKY J.W.², HARŁOZINSKA A.¹*

1) Department of Tumour Immunology, Silesian Piast's Medical Academy, Marcinkowskiego 1, 50-368 Wrocław, Poland.
2) Ukrainian Anti-Cancer Institute, Margaretenstrasse 7, 1040 Vienna, Austria.

* Author to whom correspondence should be addressed.

Summary: Several plant-derived drugs are used in medical oncology (1-3). The thiophosphoric acid-alkaloid derivative from the plant Chelidonium majus L. (Ukrain) has been produced since 1978 by Nowicky. (Austrian Patent No. 354644, Vienna, 25 January 1980). It has been reported that this drug may exert therapeutic effects in cancer patients by modulating their immune systems (4, 5-8). The aim of this study was to evaluate in vitro the possibility that Ukrain may influence the phenotype of lymphocyte subpopulations isolated from healthy donors.